Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03094715
Other study ID # TENSION
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date June 20, 2018
Est. completion date November 15, 2023

Study information

Verified date November 2023
Source University Hospital Heidelberg
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

TENSION (Efficacy and safety of ThrombEctomy iN Stroke with extended leSION and extended time window) is a prospective, open label, blinded endpoint (PROBE), European two-arm, randomized, controlled, post-market study to compare the safety and effectiveness of endovascular thrombectomy as compared to best medical care alone in the treatment of acute ischemic stroke patients with extended stroke lesions defined by an Alberta Stroke Program Early CT Score (ASPECTS) score of 3-5 and in an extended time window (up to 12 hours or unknown time of symptom onset). Up to 665 subjects will be randomized. Primary endpoint will be functional outcome assessed by the modified Rankin scale at 90 days post-stroke ("mRS shift analysis"). By this, TENSION will provide evidence of efficacy and safety of thrombectomy in an acute stroke population with uncertain benefit of endovascular stroke treatment.


Description:

This study is a prospective, open label, blinded endpoint (PROBE),European, two-arm, randomized, controlled, post-market study to compare the safety and effectiveness of endovascular thrombectomy as compared to best medical care alone in the treatment of acute ischemic stroke (AIS) in patients with extended stroke lesions defined by an ASPECT score of 3-5 and in an extended time window (up to 12 hours, or unknown time of symptom onset). This is an adaptive design study, with prospectively stated interim analyses with specified stopping rules allowing for the possibility early termination based on either a determination of study success or futility. Up to 665 subjects will be enrolled in the study and randomized for the Intention to treat analysis set. The randomization will be stratified by time from symptom onset (0-6h and 6-11h/wake up stroke), and stroke severity (NIHSS ≤18, NIHSS >18). Interim data analysis is planned after the primary endpoint has been obtained for one third and two thirds of the patients. At each of these sample sizes, the available 90-day mRS data for each treatment arm will be evaluated. Safety interim analysis will be performed after one third and two thirds of the patients have been included. Subjects who meet the inclusion criteria will be randomized in a 1:1 ratio to one of the following two treatment arms: Arm 1: best medical care Arm 2: endovascular thrombectomy and best medical care The primary objective of this study is to test efficacy and safety of thrombectomy in acute stroke patients with uncertain benefit of endovascular stroke treatment, i.e. extended ischemic lesion size with an ASPECT score of 3-5 or late (up to 12 hours) or unknown time window as compared to best medical care alone. Approximately 40 sites in Up to 20 sites in 8-10 European countries Patients presenting with acute ischemic stroke (AIS) based on focal occlusion in the M1 segment of the middle cerebral artery (MCA), and/or the intracranial segment of the distal internal carotid artery (ICA), determined by Magnetic Resonance Angiography (MRA) or Computed Tomographic Angiography (CTA), and who meet all eligibility criteria will be considered for study enrollment.


Recruitment information / eligibility

Status Terminated
Enrollment 253
Est. completion date November 15, 2023
Est. primary completion date May 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Randomization within 11 hours after stroke onset (if known) or last seen well. - Endovascular treatment is expected to be finished within 12 hours after known symptom onset or last seen well by judgment of the interventional neuroradiologist in charge (if stroke onset is known). - Patient must demonstrate clinical signs and symptoms attributable to target area of occlusion consistent with the diagnosis of ischemic stroke, including impairment of the following: language, motor function, sensation, cognition, gaze, and/or vision for at least 30 minutes without relevant improvement. - Female and male patient above 18 years of age - NIHSS Score of <26 - Signed informed consent (IC) form by patient or legal guardian, or inclusion of patient's presumptive will by investigator under emergency situation, but after consultation of an independent physician who is familiar with these types of illness if the other options are not possible according to local approval. - Prior to new focal neurological deficit, mRS score was =2. Imaging Inclusion Criteria - A new focal occlusion confirmed by imaging (MRA/CTA) to be accessible to the thrombectomy device, and located in the M1 of the middle cerebral artery (MCA) and/or the intracranial segment of the distal internal carotid artery (ICA). - CT (non-contrast CT) or DWI with an ASPECT score of 3-5 Clinical exclusion criteria - Patient is an active participant in another drug or device treatment trial for any disease state or patient is expected to start participation in another drug or device treatment trial while enrolled in this protocol, unless approved by Sponsor. - Patient has pre-existing neurological or psychiatric disease that could impede the study results or would confound the neurological or functional evaluations. - Patient has vascular disease preventing endovascular treatment (e.g. aortic dissection or aneurysm, no arterial transfemoral access) - Patient has history of contraindication for contrast medium. - Patient is known to have infective endocarditis - Patient's anticipated life expectancy is less than 6 Months12 months Imaging exclusion criteria - ExtracaranialExtracranial CT scan or MR angiography showing high grade stenosis expected to require acute stent placement (especially e.g. ICAACI stenting) during the procedure to get access to the occlusion - CT or MRI with evidence of: Mass mass effect or intracranial tumor, or hypodensity on unenhanced CT and - If CT perfusion is done per institutional standard: CBV drop on CBV maps on CTP, or, alternatively as with an ASPECT score of 0-2 - If DWI is done per institutional standard,: restricted diffusion on DWI with an ASPECT score of 0-2, or above 5

Study Design


Intervention

Device:
Thrombectomy
Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).
Other:
Best medical care
Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.

Locations

Country Name City State
Austria Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University Graz Graz
Austria Medical University Innsbruck Innsbruck
Austria Neuroradiology, Keppler University Hospital Linz Linz
Austria Department of Neurology, Reseach Institute of Neurointervention, Christian Doppler Clinic, Paracelsus Medical University Salzburg Salzburg
Canada University of Calgary Calgary Alberta
Czechia St. Anne's University Hospital Brno Brno
Czechia Faculty Hospital Hradec Kralove Hradec Kralove,
Czechia Comprehensive stroke center,University Hospital Ostrava Ostrava
Czechia Homolka Hospital Prague Prague
Czechia Dept. of Radiology, Masaryk hospital Usti nad Labem
Denmark Aalborg University Hospital Aalborg
Denmark Aarhus University Hospital Aarhus
Denmark University Hospital Rigshospitalet Copenhagen
France CHU Gabriel Montpied, Clermont-Ferrand Clermont-Ferrand
France Hôpiteaux Universitaires Paris-Sud, Hôpital Bicêtre Le Kremlin-Bicêtre
France Hôpital Pitié-Salpêtrière Paris
France Université Reims Champagne Ardenne/ Department of Neuroradiology, Hôpital Maison Blanche Reims
France CHU de Rennes/Centre Urgences-Réanimations Rennes
France CHRU Hôpiteaux de Tours / Hôpital Bretonneau Tours
Germany Universitätsklinikum KK Bochum-Langendreer Institut für Diagnostische und Interventionelle Radiologie, Neuroradiologie und Nuklearmedizin Bochum
Germany Universitätsklinikum Bonn Bonn
Germany Gesundheit Nord gGmbH Klinikverbund Bremen Bremen
Germany Klinik für Radiologie und Neuroradiologie am Klinikum Mitte Dortmund
Germany Universitätsklinikum Carl Gustav Carus Dresden Dresden
Germany Alfried Krupp Krankenhaus Rüttenscheid Essen
Germany Diakonissenkrankenhaus Flensburg Flensburg
Germany Universitätsklinikum Hamburg-Eppendorf Hamburg
Germany Neuroradiologie Universitätsklinikum Heidelberg Heidelberg
Germany Universitätsklinikum Leipzig AöR Leipzig
Germany UKSH Universitätsklinikum Schleswig-Holstein Campus Lübeck Lübeck
Germany Otto-von-Guericke-University Magdeburg Magdeburg Sachsen-Anhalt
Germany Universitätsinstitut für Diagnostische Radiologie, Neuroradiologie und Nuklearmedizin Johannes Wesling Klinikum Minden Minden Nordrhein-Westfalen
Germany Klinikum der Universität München München
Germany Technische Universität München / Klinikum rechts der Isar München
Germany Universitätsklinikum Würzburg Würzburg
Norway Haukeland University Hospital Bergen
Norway Oslo University Hospital Oslo
Norway The Arctic University of Norway Tromsø
Slovakia Comenius University's Jessenius Faculty of Medicine and University Hospital Martin
Slovakia Faculty Hospital Trnava Trnava
Spain La Paz University Hospital Madrid
Switzerland University Hospital Basel Basel

Sponsors (16)

Lead Sponsor Collaborator
University Hospital Heidelberg Aarhus University Hospital, Charles University, Czech Republic, CHU de Reims, Epidemiological and Clinical Research Information Network, Eppdata GmbH Hamburg, Germany, Europan Society for Minimally Invasive Neurological Therapy, Groupe Hospitalier Pitie-Salpetriere, Hospices Civils de Lyon, International Consortium for Health Outcome Measurement, Inc., Karolinska University Hospital, Medical University Innsbruck, Oslo University Hospital, STROKE ALLIANCE FOR EUROPE, Universitätsklinikum Hamburg-Eppendorf, University Hospital, Martin

Countries where clinical trial is conducted

Austria,  Canada,  Czechia,  Denmark,  France,  Germany,  Norway,  Slovakia,  Spain,  Switzerland, 

References & Publications (3)

Bendszus M, Bonekamp S, Berge E, Boutitie F, Brouwer P, Gizewski E, Krajina A, Pierot L, Randall G, Simonsen CZ, Zelenak K, Fiehler J, Thomalla G. A randomized controlled trial to test efficacy and safety of thrombectomy in stroke with extended lesion and extended time window. Int J Stroke. 2019 Jan;14(1):87-93. doi: 10.1177/1747493018798558. Epub 2018 Aug 29. — View Citation

Bendszus M, Fiehler J, Subtil F, Bonekamp S, Aamodt AH, Fuentes B, Gizewski ER, Hill MD, Krajina A, Pierot L, Simonsen CZ, Zelenak K, Blauenfeldt RA, Cheng B, Denis A, Deutschmann H, Dorn F, Flottmann F, Gellissen S, Gerber JC, Goyal M, Haring J, Herweh C — View Citation

van Horn N, Kniep H, Broocks G, Meyer L, Flottmann F, Bechstein M, Gotz J, Thomalla G, Bendszus M, Bonekamp S, Pfaff JAR, Dellani PR, Fiehler J, Hanning U. ASPECTS Interobserver Agreement of 100 Investigators from the TENSION Study. Clin Neuroradiol. 2021 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical outcome-modified Rankin Scale at 90 days The primary endpoint of the trial is the modified Rankin Scale (mRS) outcome at 90 days post-stroke. The primary effectiveness endpoint analysis is a chi-square test of the difference in linear trends in ordinal mRS outcomes at 90 days post-procedure between treatment groups ("mRS shift analysis"). 90 days
Secondary Independence - modified Rankin Scale=2 at 90 days Independent neurological outcomes with 90-day mRS=2 90 days
Secondary Moderate Outcome - modified Rankin Scale=3 at 90 days Moderate neurological outcome with 90-day mRS=3 90 days
Secondary Infarct volume 24 hours post procedure Infarct volume at 24 hours on post-procedure imaging 18-36 hours
Secondary Infarct growth Difference of infarct volume from infarct volume as predicted by pre-treatment imaging 18-36 hours
Secondary Functional neurological outcome at 12 months - modified Rankin Scale Functional neurological outcome at 12 months (±14 days) after stroke (simplified modified Rankin Scale questionnaire, smRSq) 12 month
Secondary Quality of life - PROMIS-10 Patient-Reported Outcomes Measurement Information System (PROMIS)-10 questionaire at 90 (±14) days. PROMIS Global-10 short form consists of 10 items that assess general domains of health and functioning including overall physical health, mental health, social health, pain, fatigue, and overall perceived quality of life. 90 days
Secondary Quality of life - EQ-5D Patient-reported functional health status and quality of life 90 (±14) days. EuroQol five-dimension scale. A standardised instrument created by the EuroQol Group as a measure of health outcome. EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which can take one of three responses reflecting severity (no problems/some or moderate problems/extreme problems). 90 days
Secondary Post-stroke depression - Patient Health Questionnaire-4 Post-stroke depression 90 (±14) days after stroke based on the Patient Health Questionnaire-4 (PHQ-4), Patient Health Questionnaire-4, Psychological distress in PHQ-4 is being rated based on 4 questions as none (0-2") mild (3-5) moderate (6-8) severe (9-12) 90 days
Secondary Parenchymal hemorrhage type 2 blood clots in >30% of the infarcted area with a substantial space-occupying effect. 90 days
Secondary modified Rankin Scale between 4-6 Death or dependency 12 month
Secondary Frequencies of Adverse Events (AE) in both treatment arms within the first 7 days Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia).
Space-occupying infarction (malignant brain edema)
New ischemic stroke
7 days
Secondary Serious AEs Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia). 12 month
Secondary Space-occupying infarction Malignant brain edema after treatment 18-36 hours
Secondary New ischemic stroke New AIS after treatment 12 month
Secondary Symptomatic intracranial hemorrhage (sICH) at 24 (18-36) hours (CT or MRI) sICH as defined in Safe Implementation of Treatments in Stroke-Monitoring Study (SITS-MOST)
parenchymal hemorrhage type 2 (PH-2)
Frequencies of Adverse Events (AE) in both treatment arms within the first 7 days after treatment
Serious AEs (SAEs), overall (all-cause mortality) and stroke-related death (i.e., related to intracranial bleeding, midline shift, brain herniation, progression of stroke symptoms, or systemic complications from stroke such as pneumonia).
Space-occupying infarction (malignant brain edema)
New ischemic stroke
18-36 hours
Secondary Cost Utility Assessment Assessment of costs from the time of randomization to the 12-months follow-up, including costs of hospitalization, institutionalized living, outpatient care, informal care provided by relatives and cost of lost productivity 12 month
Secondary Quality of life - PROMIS-10 Patient-Reported Outcomes Measurement Information System (PROMIS)-10 questionaire at 12 month (±14 days). PROMIS Global-10 short form consists of 10 items that assess general domains of health and functioning including overall physical health, mental health, social health, pain, fatigue, and overall perceived quality of life. 12 month
Secondary Quality of life - EQ-5D Health related quality of life assessment at 12 months (±14 days). EuroQol five-dimension scale. A standardised instrument created by the EuroQol Group as a measure of health outcome. EQ-5D is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each of which can take one of three responses reflecting severity (no problems/some or moderate problems/extreme problems). 12 month
Secondary Post-stroke depression - Patient Health Questionnaire-4 Health related quality of life assessment at 12 months (±14 days) to assess post stroke depression - Patient Health Questionnaire-4 (PHQ-4) Psychological distress in PHQ-4 is being rated based on 4 questions as none (0-2") mild (3-5) moderate (6-8) severe (9-12) 12 month
See also
  Status Clinical Trial Phase
Recruiting NCT05378035 - DOAC in Chinese Patients With Atrial Fibrillation
Completed NCT03574038 - Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke N/A
Completed NCT03679637 - Tablet-based Aphasia Therapy in the Acute Phase After Stroke N/A
Completed NCT03633422 - Evaluation of Stroke Patient Screening
Completed NCT04088578 - VNS-supplemented Motor Retraining After Stroke N/A
Not yet recruiting NCT05534360 - Tenecteplase Treatment in Ischemic Stroke Registry
Withdrawn NCT04991038 - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients N/A
Not yet recruiting NCT04105322 - Effects of Kinesio Taping on Balance and Functional Performance in Stroke Patients N/A
Withdrawn NCT05786170 - ERILs Und SNILs Unter SOC N/A
Recruiting NCT03132558 - Contrast Induced Acute Kidney in Patients With Acute Stroke N/A
Completed NCT02893631 - Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
Active, not recruiting NCT02274727 - Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Completed NCT02225730 - Imaging Collaterals in Acute Stroke (iCAS)
Terminated NCT01705353 - The Role of HMGB-1 in Chronic Stroke N/A
Active, not recruiting NCT01581502 - SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF) N/A
Completed NCT01182818 - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease N/A
Completed NCT00761982 - Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment. Phase 1/Phase 2
Completed NCT00535197 - Autologous Bone Marrow Stem Cells in Ischemic Stroke. Phase 1/Phase 2
Terminated NCT00132509 - FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke Phase 2
Recruiting NCT05760326 - Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients